التفاصيل البيبلوغرافية
| العنوان: |
Effectiveness of XBB.1.5 monovalent COVID-19 vaccines during a period of XBB.1.5 dominance in EU/EEA countries, October to November 2023 |
| المؤلفون: |
Monge, Susana, Humphreys, James, Nicolay, Nathalie, Braeye, Toon, Evercooren, Izaak Van, Hansen, Christian Holm, Emborg, Hanne-Dorthe, Sacco, Chiara, Urdiales, Alberto Mateo, Castilla, Jesus, Martínez-Baz, Iván, Gier, Brechje de, Hahné, Susan, Meijerink, Hinta, Kristoffersen, Anja Bråthen, Machado, Ausenda, Soares, Patricia, Nardone, Anthony, Bacci, Sabrina, Kissling, Esther, Nunes, Baltazar |
| بيانات النشر: |
Authorea, Inc. |
| سنة النشر: |
2024 |
| المجموعة: |
The Winnower (via CrossRef) |
| الوصف: |
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in ≥65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted Hazard Ratios and derive VE. VE for COVID-10 hospitalisation and death was, respectively, 67% (95%CI: 60-72) and 68% (95%CI: 44-82) in 65–79-year-olds, and 64% (95%CI: 49-75) and 74% (95%CI: 56-85) in ≥80-year-olds. Results indicate that periodic vaccination of individuals ≥65 years has an ongoing benefit, and support the current vaccination strategies in the EU/EEA. |
| نوع الوثيقة: |
other/unknown material |
| اللغة: |
unknown |
| DOI: |
10.22541/au.171463229.90522448/v1 |
| الإتاحة: |
https://doi.org/10.22541/au.171463229.90522448/v1Test |
| رقم الانضمام: |
edsbas.6ABD2C7C |
| قاعدة البيانات: |
BASE |
